Reducing Patents Gets Attention From House Freedom Caucus At Pricing Hearing
House Oversight Committee Ranking Member Jim Jordan suggests that Congress may need to re-evaluate the length of pharma patents and FDA exclusivities.
You may also be interested in...
Rx Patent Reform Gets Renewed Interest From GOP As Alternative To Price Negotiation
A Republican congressman and witness discuss shortened IP protections while criticizing Nancy Pelosi's drug price negotiation plan.
Drug Pricing And The AOC Effect
Alexandria Ocasio-Cortez’ social media celebrity gives the first-year Democratic member of Congress an outsize influence – and she is making pharmaceutical industry profits a priority target. But she is also having a unifying effect in rallying Republicans behind industry.
Drug Pricing And The Trump Effect: How To Make A High Profile Hearing Vanish
Without President Trump’s focus on drug pricing, it is hard to imagine that seven top industry executives would have had to face a grilling in the US Senate Finance Committee. But they can also thank Trump’s indiscretions for helping ensure that the hearing was barely even a one-day story.